4.6 Article

Application of Proteogenomics to Urine Analysis towards the Identification of Novel Biomarkers of Prostate Cancer: An Exploratory Study

Journal

CANCERS
Volume 14, Issue 8, Pages -

Publisher

MDPI
DOI: 10.3390/cancers14082001

Keywords

prostate cancer; urine; human; biomarker; proteome; proteogenome; label-free quantitation; immunoblot

Categories

Funding

  1. Portuguese Foundation for Science and Technology (FCT) [UIDB/IC/00051/2020, UIDP/00051/2020, UIDB/04501/2020, POCI-01-0145-FEDER-007628]
  2. European Union [UIDB/IC/00051/2020, UIDP/00051/2020, UIDB/04501/2020, POCI-01-0145-FEDER-007628]
  3. QREN [UIDB/IC/00051/2020, UIDP/00051/2020, UIDB/04501/2020, POCI-01-0145-FEDER-007628]
  4. FEDER [UIDB/IC/00051/2020, UIDP/00051/2020, UIDB/04501/2020, POCI-01-0145-FEDER-007628]
  5. COMPETE [UIDB/IC/00051/2020, UIDP/00051/2020, UIDB/04501/2020, POCI-01-0145-FEDER-007628]
  6. FCT QOPNA [FCT UID/QUI/00062/2019]
  7. FCT LAQV/REQUIMTE [UIDB/50006/2020]
  8. FCT DOCnet [NORTE-01-0145-FEDER-000003]
  9. Norte Portugal Regional Operational Programme (NORTE 2020), under the PORTUGAL 2020 Partnership Agreement, through the European Regional Development Fund (ERDF)
  10. [SFRH/BD/136904/2018]
  11. [IF/00286/2015]

Ask authors/readers for more resources

This study utilized proteomics and proteogenomics approaches to identify dysregulated mutant protein isoforms in urine from prostate cancer patients. These findings offer promising opportunities for the research and development of non-invasive biomarkers for prostate cancer detection.
Simple Summary Prostate cancer (PCa) is one of the most common cancers. Due to the limited and invasive approaches for PCa diagnosis, it is crucial to identify more accurate and non-invasive biomarkers for its detection. The aim of our study was to non-invasively uncover new protein targets for detecting PCa using a proteomics and proteogenomics approach. This work identified several dysregulated mutant protein isoforms in urine from PCa patients, some of them predicted to have a protective or an adverse role in these patients. These results are promising given urine's non-invasive nature and offers an auspicious opportunity for research and development of PCa biomarkers. To identify new protein targets for PCa detection, first, a shotgun discovery experiment was performed to characterize the urinary proteome of PCa patients. This revealed 18 differentially abundant urinary proteins in PCa patients. Second, selected targets were clinically tested by immunoblot, and the soluble E-cadherin fragment was detected for the first time in the urine of PCa patients. Third, the proteogenome landscape of these PCa patients was characterized, revealing 1665 mutant protein isoforms. Statistical analysis revealed 6 differentially abundant mutant protein isoforms in PCa patients. Analysis of the likely effects of mutations on protein function and PPIs involving the dysregulated mutant protein isoforms suggests a protective role of mutations HSPG2*Q1062H and VASN*R161Q and an adverse role of AMBP*A286G and CD55*S162L in PCa patients. This work originally characterized the urinary proteome, focusing on the proteogenome profile of PCa patients, which is usually overlooked in the analysis of PCa and body fluids. Combined analysis of mass spectrometry data using two different software packages was performed for the first time in the context of PCa, which increased the robustness of the data analysis. The application of proteogenomics to urine proteomic analysis can be very enriching in mutation-related diseases such as cancer.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available